Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Unknown2
Terminated1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07581834Phase 2Recruiting

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

NCT03939156Unknown

Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer

NCT01499160Phase 2Terminated

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

NCT03373708Phase 2Unknown

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Showing all 4 trials

Research Network

Activity Timeline